Heart Failure With Preserved Ejection Fraction: Clinical Trials

27 trials for Heart Failure With Preserved Ejection Fraction, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 7 unknown, 6 recruiting, 3 terminated. 27 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 427Completed 8, Unknown 7, Recruiting 6, Terminated 3, Not yet recruiting 2, Withdrawn 1

Follow Heart Failure With Preserved Ejection Fraction: new trials by email Literature Review of Heart Failure With Preserved Ejection Fraction trials Research Report on Heart Failure With Preserved Ejection Fraction

Trials (filtered) newest first · largest first

All 27 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
IV Iron Therapy for Older Adults With Heart Failure With Preserved Ejection Fraction and Iron Deficiency
Ferric derisomaltose, Placebo (normal saline) - Heart Failure With Preserved Ejection Fraction, Iron Deficiency
Phase 4Not yet recruitingDuke University3002026-11-012026-10-15
Finerenone and Cardiac Remodeling in HFpEF
Finerenone, Standard of care for HFpEF Description: - Heart Failure With Preserved Ejection Fraction
Phase 4Not yet recruitingAssiut University1942026-09-202026-09-22
Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction
Sacubitril-valsartan, Valsartan - Heart Failure With Preserved Ejection Fraction, Myocardial Fibrosis
Phase 4WithdrawnBrigham and Women's Hospital2026-08-272026-08-31
Incretin Therapies in Obesity-related HFpEF
Tirzepatide - Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction
Phase 4RecruitingColumbia University502026-08-072026-08-24
SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF
Dapagliflozin tablet, Hypertonic Saline Solution, 1 Ml, Furosemide Injection - Heart Failure Acute, Diabetes Type 2
Phase 4UnknownUniversity of Palermo5442024-06-012024-06-06
EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease
Empagliflozin 25 MG, Placebo - Heart Failure With Preserved Ejection Fraction, End Stage Renal Disease on Dialysis
Phase 4RecruitingNational Taiwan University Hospital1502024-03-052024-12-16
Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation
Sacubitril-valsartan, Standard of care - Heart Failure With Preserved Ejection Fraction, Functional Mitral Regurgitation
Phase 4CompletedZiekenhuis Oost-Limburg842024-02-292026-06-08
A Preliminary Study for INFORMED
Beta blocker - Heart Failure, Heart Failure, Diastolic
Phase 4RecruitingWeill Medical College of Cornell University182024-02-072026-08-21
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life
Ferric derisomaltose, Placebo - Heart Failure With Preserved Ejection Fraction, Iron Deficiencies
Phase 4RecruitingChina-Japan Friendship Hospital1702023-08-012026-11-06
Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants
Pioglitazone, Placebo - Type 2 Diabetes Mellitus in Obese, Heart Failure With Preserved Ejection Fraction
Phase 4RecruitingThe University of Texas Health Science Center at San Antonio782023-07-102026-09-22
CAtheter-Based Ablation of Atrial Fibrillation Compared to Conventional Treatment in Patients With Heart Failure With Preserved Ejection Fraction
CE-marked Catheter Ablation - Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction
Phase 4RecruitingCharite University, Berlin, Germany15482023-03-012023-03-06
Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment - Heart Failure With Preserved Ejection Fraction, Microvascular Dysfunction
Phase 4UnknownMaastricht University Medical Center482023-02-132023-09-21
EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection Fraction
Empagliflozin 10 Mg - Heart Failure, Heart Failure With Preserved Ejection Fraction
Phase 4UnknownZhijun Sun1002022-12-152022-12-23
Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Empagliflozin 10 MG - Heart Failure, Heart Failure With Preserved Ejection Fraction
Phase 4UnknownZhijun Sun1002022-11-052023-03-07
Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients
Sotagliflozin, Placebo - Heart Failure With Preserved Ejection Fraction
Phase 4CompletedJuan Badimon882022-10-262026-06-24
Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial
Low dose combination polydiuretic therapy, Comparator monotherapy empagliflozin - Heart Failure With Preserved Ejection Fraction
Phase 4TerminatedThe George Institute32022-10-012024-11-21
Use of SGLT2i in noHCM With HFpEF
Empagliflozin 10 MG - Hypertrophic Cardiomyopathy, Heart Failure With Preserved Ejection Fraction
Phase 4UnknownChina National Center for Cardiovascular Diseases942022-08-012024-05-06
BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF
Amlodipine Besylate, Metoprolol Succinate - Heart Failure With Preserved Ejection Fraction, Hypertension
Phase 4CompletedUniversity of Pennsylvania502021-12-012026-01-30
Carvedilol in HF With Preserved EF
Carvedilol, Placebo - Heart Failure With Preserved Ejection Fraction, Beta Blocker
Phase 4CompletedSeoul National University Bundang Hospital632021-11-172026-05-19
Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction
Empagliflozin 10 MG - Heart Failure with Preserved Ejection Fraction, Heart Failure, Diastolic
Phase 4CompletedUniversity of Texas Southwestern Medical Center82021-11-092024-09-19

Showing 20 of 27. Sign in to see all of them.

Narrower conditions

Heart Failure (10)  ·  Heart Failure, Diastolic (8)  ·  Heart Diseases (3)  ·  Diabetes Mellitus (2)  ·  Diabetes Mellitus, Type 2 (2)  ·  Hypertension, Pulmonary (2)  ·  Iron Deficiencies (2)  ·  Atrial Fibrillation (1)  ·  Cardiomyopathy, Hypertrophic (1)  ·  Hypertension (1)  ·  Kidney Failure, Chronic (1)  ·  Motor Activity (1)  ·  Obesity (1)

Broader conditions

Cardiovascular Diseases (16)  ·  Heart Diseases (12)  ·  Nutritional and Metabolic Diseases (6)  ·  Metabolic Diseases (5)  ·  Heart Failure (4)  ·  Endocrine System Diseases (3)  ·  Glucose Metabolism Disorders (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Vascular Diseases (3)  ·  Hypertension (2)  ·  Iron Metabolism Disorders (2)  ·  Lung Diseases (2)  ·  Pathologic Processes (2)  ·  Respiratory Tract Diseases (2)  ·  Aortic Stenosis, Subvalvular (1)

Interventions

empagliflozin (7)  ·  Adrenergic beta-Antagonists (3)  ·  Carvedilol (3)  ·  Metoprolol (3)  ·  Nebivolol (3)  ·  sacubitril and valsartan sodium hydrate drug combination (3)  ·  Acebutolol (2)  ·  Atenolol (2)  ·  Betaxolol (2)  ·  Bisoprolol (2)  ·  Labetalol (2)  ·  Nadolol (2)  ·  Penbutolol (2)  ·  Pindolol (2)  ·  Propranolol (2)

Sponsors

Weill Medical College of Cornell University (3)  ·  University of Texas Southwestern Medical Center (2)  ·  Zhijun Sun (2)  ·  Assiut University (1)  ·  Brigham and Women's Hospital (1)  ·  Charite University, Berlin, Germany (1)  ·  China National Center for Cardiovascular Diseases (1)  ·  China-Japan Friendship Hospital (1)  ·  Columbia University (1)  ·  Duke University (1)  ·  Hospital General Universitario Gregorio MaraƱon (1)  ·  Juan Badimon (1)  ·  Maastricht University Medical Center (1)  ·  Mayo Clinic (1)  ·  National Taiwan University Hospital (1)

Countries

United States (12)  ·  China (4)  ·  South Korea (2)  ·  Australia (1)  ·  Belgium (1)  ·  Germany (1)  ·  Netherlands (1)  ·  Spain (1)  ·  Taiwan (1)

Top investigators

Parag Goyal, MD (2)  ·  Abdul Parwani, Dr. (1)  ·  Ahmed A Ahmed, prof (1)  ·  Burkert Pieske, Prof. Dr. (1)  ·  Carlos G Santos-Gallego, MD (1)  ·  Chih-Cheng Wu, MD. PhD (1)  ·  Clare Arnott (1)  ·  Dong-Ju Choi, MD, PhD (1)  ·  Donna SH Lin, MD (1)  ·  Elissa A Driggin, MD (1)  ·  Fernando Torres, MD (1)  ·  Giuseppe Miceli, PhD (1)  ·  Javier Bermejo Thomas, MD, PhD (1)  ·  Juan J Badimon (1)

Results publications

PMID 15963399, PMID 20607462, PMID 21329845, PMID 21440872, PMID 21885793, PMID 22980301, PMID 22983988, PMID 23743396, PMID 26240596, PMID 26378978, PMID 28402411, PMID 29724346, PMID 31540679, PMID 32139695, PMID 32709292, PMID 32970396, PMID 34447992, PMID 35241246, PMID 36607775, PMID 37318685, PMID 38737708, PMID 40281528, PMID 40855136, PMID 42104906, PMID 42137945

NIH funding

K76AG064428 (2), 2019 (1), K23GM112014 (1), K23HL168163 (1), R01AG097715 (1), R21AG053512 (1)